Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases

Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases

Abstract Background Rare diseases are a global public health concern, affecting an estimated 350 million individuals. Only 5% of approximately 7000 known rare diseases have a treatment, and only about half have a patient advocacy organization. Biopharmaceutical companies face complex challenges in d...

Full description

Bibliographic Details
Main Authors: Susan Stein, Elizabeth Bogard, Nicole Boice, Vivian Fernandez, Tessa Field, Alan Gilstrap, Susan R. Kahn, Jane Larkindale, Toni Mathieson
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Best practices
Biopharmaceutical
Guidelines
Partnership
Patient advocacy
Rare disease
Online Access:http://link.springer.com/article/10.1186/s13023-018-0761-2

Internet

http://link.springer.com/article/10.1186/s13023-018-0761-2

Similar Items